Back

Sodium-glucose co-transporter-2 inhibitors and the risk of major arrhythmias: a meta-analysis of the cardiovascular and renal outcome trials

27 August 2021 (08:00 - 20:00)
Organised by:
Congress Presentation Part of: Congress committee e-posters choice in pharmacology and pharmacotherapy Antidiabetic Pharmacotherapy ESC Premium Access ESC Congress 2021 - The Digital Experience

About the speaker

Photo
Doctor Aristi Boulmpou

Radboud University Medical Centre, Nijmegen (Netherlands (The))

17 More presentations in this session

Presentation thumbnail
Gastrointestinal bleeding risk following concomitant treatment with oral glucocorticoids in patients with atrial fibrillation on direct-acting oral anticoagulants
Mr A. Holt (Copenhagen, DK)
Abstract Slides
Presentation thumbnail
Usage and risk with phosphodiesterase type 5 inhibitors in male patients with chronic ischemic heart disease on oral organic nitrates
Mr A. Holt (Copenhagen, DK)
Abstract Slides
Presentation thumbnail
PCSK9 inhibition with alirocumab decreases plasma lipoprotein(a) concentration by a dual kinetic mechanism of action
Mr Q. Ying (Ningbo, CN)
Abstract Slides
Presentation thumbnail
Antifibrotic and anti-inflammatory effects of the selective nonsteroidal MR antagonist finerenone in preclinical pulmonary fibrosis
Doctor M. Delbeck (Wuppertal, DE)
Abstract Slides
Presentation thumbnail
Aspirin vs. P2Y12 inhibitors with anticoagulation therapy for atrial fibrillation: insights from the AFIRE trial
Assistant Professor H. Fukaya (Sagamihara, JP)
Abstract Slides

Access the full session

Session thumbnail
Congress committee e-posters choice in pharmacology and pharmacotherapy

The Event

Event poster

ESC Congress 2021 - The Digital Experience

27 August 2021 08:00 CET
You may be interested in
thumbnail
Congress Presentation
Risk of death with sodium-glucose co-transporter-2 inhibitors across the hallmark cardiovascular and renal outcome trials: an updated meta-analysis
27 August 2021
thumbnail
Congress Session
Insights into arrhythmia mechanisms
26 August 2022
thumbnail
Congress Presentation
Insulin treatment is associated with increased risk of device-treated ventricular tachyarrhythmia in patients with diabetes and heart failure
2 September 2019
thumbnail
Congress Presentation
Divergent electrophysiologic safety profile of dapagliflozin and empagliflozin in a whole-heart model
27 August 2022

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources